Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation
<p>Abstract</p> <p>Background</p> <p>Acromegaly, an orphan disease usually caused by a benign pituitary tumour, is characterised by hyper-secretion of growth hormone (GH) and insulin-like growth factor I (IGF-1). It is associated with reduced life expectancy, cardiovasc...
Main Authors: | Connock Martin J, Adi Yaser, Moore David J, Bayliss Sue |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2009-10-01
|
Series: | BMC Endocrine Disorders |
Online Access: | http://www.biomedcentral.com/1472-6823/9/20 |
Similar Items
-
Pegvisomant for acromegaly: does it always works?
by: Sebastian J. Neggers, et al. -
Brazilian multicenter study on pegvisomant treatment in acromegaly
by: Cesar L. Boguszewski, et al. -
Pegvisomant in acromegaly: a multicenter real-life study in Argentina
by: Natalia Ximena Garcia Basavilbaso, et al. -
Pegvisomant and current approaches to the medical treatment of acromegaly (literature review and case report)
by: Larisa K. Dzeranova, et al.
Published: (2020-03-01) -
Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies
by: Lingyun Ma, et al.
Published: (2020-08-01)